Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 11/20 | 0.58 |
| ▸ | FNTB | P49356 | 11/20 | 0.58 |
| ▸ | HRAS | P01112 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1978262 | 0.84 | FNTA (0.60) | FNTAFNTB | |
| SCHEMBL13611706 | 0.82 | FNTA (0.58) | FNTAFNTB | |
| SCHEMBL14289895 | 0.82 | FNTA (0.58) | FNTAFNTB | |
| SCHEMBL2601321 | 0.82 | HTR2C (0.47) | FNTAFNTB | |
| SCHEMBL12050758 | 0.81 | P2RX7 (0.41) | FNTAFNTB | |
| SCHEMBL14102072 | 0.80 | MEN1 (0.58) | FNTAFNTBHRASKRAS | |
| SCHEMBL6991517 | 0.79 | MAP3K14 (0.44) | FNTAFNTB | |
| SCHEMBL13604336 | 0.79 | FNTA (0.55) | FNTAFNTB | |
| SCHEMBL14415964 | 0.79 | OPRL1 (0.48) | FNTAFNTB | |
| SCHEMBL6995947 | 0.78 | FNTA (0.52) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888562-B1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARM HOLDING (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-0723540-A1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1996-07-31 | — | — | EP | disclosed |
| EP-0535152-B1 | Bis-benzo or benzopyrido cyclo hepta piperidene, piperidylene and piperazine compounds as PAF antagonists and compositions thereof. | SCHERING CORP (US) | 1995-08-09 | — | — | EP | disclosed |
| US-5422351-A | Antiallergens; antiinflammatory agents | SCHERING CORPORATION (US) | 1995-06-06 | — | — | US | disclosed |
| WO-1995010516-A1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1995-04-20 | — | — | WO | disclosed |
| WO-1995010515-A1 | TRICYCLIC CARBAMATE COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1995-04-20 | — | — | WO | disclosed |
| EP-0396083-B1 | Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use | SCHERING CORP (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5151423-A | Antiinflammatory agents or antiallergens | SCHERING CORPORATION (US) | 1992-09-29 | — | — | US | disclosed |
| EP-0471750-A1 | HETEROCYCLIC N-OXIDE DERIVATIVES OF SUBSTITUTED BENZO 5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1992-02-26 | — | — | EP | disclosed |
| WO-1990013548-A1 | HETEROCYCLIC N-OXIDE DERIVATIVES OF SUBSTITUTED BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1990-11-15 | — | — | WO | disclosed |
| EP-0396083-A1 | Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use | SCHERING CORPORATION (US) | 1990-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP3, DPP7 | FNTA 3223/4885FNTB 3531/4885HRAS 4604/4885 |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP7 | FNTA 3223/4885FNTB 3531/4885HRAS 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.